H. PYLORI-ІНФЕКЦІЯ У ПАЦІЄНТІВ ІЗ ХРОНІЧНИМ ОБСТРУКТИВНИМ ЗАХВОРЮВАННЯМ ЛЕГЕНЬ У ПОЄДНАННІ З ГАСТРОПАТІЯМИ

Abstract

Recently, the number of publications on the link between respiratory diseases and Helicobacter Pylori infection was growing. Especially, this was observed for COPD , bronchial asthma, chronic bronchitis and lung cancer.The aim of the study – to evaluate the correlation between the levels of H. pylori IgG and spirometry data for COPD patients.Materials and Methods. The total of 68 patients were examined, including 44 males (64.7 %) and 24 females (35.3 %). The patients were divided into two groups; group 1 included 23 patients mainly with stage 2 COPD , whereas group 2 made up of 45 COPD stage 3 patients. All the patients underwent general clinical tests, namely the collection of anamnestic data establishing the risk factors, course, COPD duration and recurrence rate, chest X-ray and spirometry.Results and Discussion. The examination of 68 patients with stage 2 and stage 3 COPD comorbid with gastroduodenal erosions and ulcers revealed smoking and H. pylori infection to be the major risk factors. The smoking history was significantly longer for stage 3 COPD patients, and there was a weak correlation between H. pylori IgG and smoking history length. Erosive and ulcerative defects were observed in both patient groups. H. pylori IgG levels were significantly higher in Stage 3 COPD patients, as compared to Stage 2 patients. The highlight of the work was to detect the correlation between helicobacter infection and both FEV 1 and FVC, while a significant decrease in these parameters backed with H. pylori infection was observed.Conclusions. The course of COPD is often accompanied by the appearance of erosive-ulcerative lesions of the gastroduodenal zone. Detection of negative correlation bonds between FEV 1 and FVC and H. pylori infection indicates a possible pathogenetic role of the helicobacter in the development of COPD . Provisions of Maastricht V should be used when detecting H. pylori infection with COPD patients.